Inhibitor development, immune tolerance and prophylaxis in haemophilia A--the need for an evidence-based approach.
Mannucci
P M
PM
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital of Milan, Milan, Italy. piermannuccio.mannucci@unimi.it
Abshire
T
T
Dimichele
D
D
Santagostino
E
E
Blanchette
V
V
D019774:Blood Coagulation Factor Inhibitors / Q000097:blood*; D003029:Coagulants / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000276:immunology; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005169:Factor VIII / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000276:immunology; D006467:Hemophilia A / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D007518:Isoantibodies / Q000097:blood; D008297:Male; D012307:Risk Factors
D019774:Blood Coagulation Factor Inhibitors; D003029:Coagulants; D007518:Isoantibodies; D005169:Factor VIII